Multimodal approach in the treatment of generalized malignancies of the gastrointestinal tract

Česká verzia

Authors: Z. Bielčiková ¹ ; Ulrych J. ² ; Frýba V. ² ; Hrabák P. ³ ; Zubaľ M. ¹ ; Křížová . L ¹; L. Petruželka ¹
Authors place of work: Onkologická klinika 1. LF UK a VFN v Praze ¹; I. chirurgická klinika – hrudní, břišní a úrazové chirurgie 1. LF UK a VFN v Praze ²; IV. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze ³
Published in the journal: Gastroent Hepatol 2022; 76(5): 409-417
Category: Gastrointestinal Oncology: Review Article
doi: https://doi.org/10.48095/ccgh2022409

Summary

Background: More than 10,000 patients are diagnosed with malignant tumors of the intestine, pancreas, esophagus and stomach in the Czech Republic each year. A significant proportion of patients relapse or are primary diagnosed at a locally advanced inoperable or metastatic stage. The prognosis of these patients can be influenced by oncological treatment and in many cases also by surgical, endoscopic or radiological intervention. Methods: The article summarizes treatment options of patients with advanced or metastatic malignancies of the gastrointestinal tract from the perspective of oncologist and surgeon in order to present oncological data on prognosis of patients and surgical methods of treatment to other members of the multidisciplinary team. Endoscopic methods are consulted with gastroenterologist. Results: The importance of surgery is not the same for all mentioned cancer types and it is influenced by many variables. The highest benefit of the surgical treatment has resection of liver metastases of colorectal cancer, on the other hand, surgery has only limited palliative impact in pancreatic cancer patients. Conclusions: A multimodal approach to the treatment of tumors of the gastrointestinal tract offers the inclusion of surgical treatment at the present time even where it was not routinely recommended in the past. The condition for the correct indication of surgery is a multidisciplinary assessment of each individual patient.

Keywords:

colorectal cancer – Pancreatic cancer – Esophageal cancer – stomach cancer – GIT malignancies – relapses – surgergical procedures

Zdroje

1. Tsai MS, Su YH, Ho MC et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 2007; 14 (2): 786–794. doi: 10.1245/s10434-006-9215-5.

2. Liu C, Wang T, Yang J et al. Distant Metastasis Pattern and Prognostic Prediction Model of Colorectal Cancer Patients Based on Big Data Mining. Front Oncol 2022; 12: 878805. doi: 10.3389/fonc.2022.878805.

3. Elias D, Liberale G, Vernerey D et al. Hepatic and extrahepatic colorectal metastases: When resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005; 12 (11): 900–909. doi: 10.1245/ASO.2005.01.010.

4. Zucchelli G, Moretto R, Rossini D et al. Oligometastatic colorectal cancer: Prognostic implications of tumor load, role of locoregional treatments, and of first-line therapy intensification – A pooled analysis of TRIBE and TRIBE2 studies by GONO. J Clin Oncol 2020; 38 (4_suppl): 12. doi: 10.1200/jco.2020.38.4_ suppl.12.

5. Jácome AA, Vreeland TJ, Johnson B et al. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. Br J Cancer 2021; 124 (4): 797–804. doi: 10.1038/s41416-020- 01169-w.

6. Bulut G, Oytun MG, Almuradova E et al. Contribution of “complete response to treatment” to survival in patients with unresectable metastatic colorectal cancer: A retrospective analysis. PLoS One 2021; 16: e0259622. doi: 10.1371/journal.pone.0259622.

7. Kanas GP, Taylor A, Primrose JN et al. Survival after liver resection in metastatic colorectal cancer: Review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4 (1): 1203–1213. doi: 10.2147/CLEP.S34285.

8. Creasy JM, Sadot E, Koerkamp BG et al. Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery 2018; 163 (6): 1238–1244. doi: 10.1016/j.surg.2018.01.004.

9. Mise Y, Aloia TA, Brudvik KW et al. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg 2016; 263 (1): 146–152. doi: 10.1097/SLA.0000000000001194.

10. Beckers P, Berzenji L, Yogeswaran SK et al. Pulmonary metastasectomy in colorectal carcinoma. J Thorac Dis 2021; 13 (4): 2628–2635. doi: 10.21037/jtd-2019-pm-14.

11. Tuca A, Guell E, Martinez-Losada E et al. Malignant bowel obstruction in advanced cancer patients: Epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res 2012; 4 (1): 159–169. doi: 10.2147/CMAR.S29297.

12. Corona E, Yang L, Esrailian E et. al. Trends in Esophageal Cancer Mortality and Stage at Diagnosis by Race and Ethnicity in the United States. Cancer Causes Control 2021; 32 (8): 883–894. doi: 10.1007/s10552-021-01443-z.

13. Procopio F, Marano S, Gentile D et al. Management of liver oligometastatic esophageal cancer: Overview and critical analysis of the different loco-regional treatments. Cancers (Basel) 2020; 12 (1): 20. doi: 10.3390/cancers12010020.

14. Riihimäki M, Hemminki A, Sundquist K et al. Metastatic spread in patients with gastric cancer. Oncotarget 2016; 7 (32): 52307–52316. doi: 10.18632/oncotarget.10740.

15. Li SC, Lee CH, Hung CL et al. Surgical resection of metachronous hepatic metastases from gastric cancer improves long-term survival: A population-based study. PLoS One 2017; 12 (7): e0182255. doi: 10.1371/journal.pone. 0182255.

16. Parry K, Visser E, van Rossum PSN et al. Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent. Ann Surg Oncol 2015; 22 (Suppl_3): S1292–S1300. doi: 10.1245/s10434-015-4840-5.

17. Lordick F, Carneiro F, Cascinu S et al. Gastric cancer: ESMO Clinical Practice Guideline for diag- nosis, treatment and follow-up. Ann Oncol 2022; S0923–7534 (22) 01851-8. doi: 10.1016/ J.ANNONC.2022.07.004.

18. Marte G, Tufo A, Steccanella F et al. Efficacy of surgery for the treatment of gastric cancer liver metastases: A systematic review of the literature and meta-analysis of prognostic factors. J Clin Med 2021; 10 (5): 1141. doi: 10.3390/jcm10051141.

19. Granieri S, Altomare M, Bruno F et al. Surgical treatment of gastric cancer liver metastases: Systematic review and meta-analysis of long-term outcomes and prognostic factors. Crit Rev Oncol Hematol 2021; 163: 103313. doi: 10.1016/j.critrevonc.2021.103313.

20. Schizas D, Lazaridis II, Moris D et al. The role of surgical treatment in isolated organ recurrence of esophageal cancer-a systematic review of the literature. World J Surg Oncol 2018; 16 (1): 55. doi: 10.1186/s12957-018-13 57-y.

21. Alyami M, Hübner M, Grass F et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 2019; 20 (7): e368–e377. doi: 10.1016/S1470-2045 (19) 30318-3.

22. Coffey MR, Bachman KC, Worrell SG et al. Palliative Surgery Outcomes for Patients with Esophageal Cancer: An NCDB Analysis. J Surg Res 2021; 267: 229–234. doi: 10.1016/ j.jss.2021.05.013.

23. Iwasaki H, Mizushima T, Suzuki Y et al. Factors That Affect Stent-Related Complications in Patients with Malignant Obstruction of the Esophagus or Gastric Cardia. Gut Liver 2017; 11 (1): 47–54. doi: 10.5009/gnl16172.

24. Spaander MCW, van der Bogt RD, Baron TH et al. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021. Endoscopy 2021; 53 (7): 751–762. doi: 10.1055/a-1475-0063.

25. Ghoshal UC, Kumar V. Antroduodenal stenting for malignant gastric outlet obstruction: technique and outcome. J Dig Endosc 2019; 10 (1). doi: 10.4103/jde.JDE_64_18.

26. Itoi T, Baron TH, Khashab MA et al. Technical review of endoscopic ultrasonography-guided gastroenterostomy in 2017. Dig Endosc 2017; 29 (4): 495–502. doi: 10.1111/den.12794.

27. Kouanda A, Binmoeller K, Hamerski C et al. Endoscopic ultrasound-guided gastroenterostomy versus open surgical gastrojejunostomy: clinical outcomes and cost effectiveness analysis. Surg Endosc 2021; 35 (12): 7058–7067. doi: 10.1007/s00464-020-08221-z.

28. Perez-Miranda M, Tyberg A, Poletto D et al. EUS-guided Gastrojejunostomy Versus Laparoscopic Gastrojejunostomy: An International Collaborative Study. J Clin Gastroenterol 2017; 51 (10): 896–899. doi: 10.1097/MCG.000 0000000000887.

29. Ge PS, Young JY, Dong W et al. EUS-guided gastroenterostomy versus enteral stent placement for palliation of malignant gastric outlet obstruction. Surg Endosc 2019; 33 (10): 3404–3411. doi: 10.1007/s00464-018-066 36-3.

30. Cominardi A, Tamanini G, Brighi N et al. Conservative management of malignant gastric outlet obstruction syndrome-evidence based evaluation of endoscopic ultrasound-guided gastroentero-anastomosis. World J Gastrointest Oncol 2021; 13 (9): 1086–1098. doi: 10.4251/wjgo.v13.i9.1086.

31. Kerdsirichairat T, Irani S, Yang J et al. Durability and long-term outcomes of direct EUS-guided gastroenterostomy using lumen-apposing metal stents for gastric outlet obstruction. Endosc Int Open 2019; 7 (2): E144–E150. doi: 10.1055/a-0799-9939.

32. van Veldhuisen E, van den Oord C, Brada LJ et al. Locally advanced pancreatic cancer: Work-up, staging, and local intervention strategies. Cancers (Basel) 2019; 11 (7): 976. doi: 10.3390/cancers11070976.

33. Gillen S, Schuster T, Büschenfelde CM Zum et al. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7 (4): e1000267. doi: 10.1371/journal.pmed.1000267.

34. Petrelli F, Coinu A, Borgonovo K et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: A meta-analytical review of published studies. Pancreas 2015; 44 (4): 515–521. doi: 10.1097/MPA.0000000000000 314.

35. Latenstein AEJ, van Roessel S, van der Geest LGM et al. Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Ann Surg Oncol 2020; 27 (7): 2516–2524. doi: 10.1245/s10434-020-08235-w.

36. Golan T, Kanji ZS, Epelbaum R et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014; 111 (6): 1132–1138. doi: 10.1038/bjc. 2014.418.

37. Cloyd JM, Crane CH, Koay EJ et al. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer 2016; 122 (17): 2671–2679. doi: 10.1002/cncr.30117.

38. Gleisner AL, Assumpcao L, Cameron JL et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 2007; 110 (11): 973–977. doi: 10.1002/cncr.23074.

39. Zanini N, Lombardi R, Masetti M et al. Surgery for isolated liver metastases from pancreatic cancer. Updates Surg 2015; 67 (1): 19–25. doi: 10.1007/s13304-015-0283-6.

40. Timmer FEF, Geboers B, Nieuwenhuizen S et al. Locoregional treatment of metastatic pancreatic cancer utilizing resection, ablation and embolization: A systematic review. Cancers (Basel) 2021; 13 (7): 1608. doi: 10.3390/ cancers13071608.

41. Perinel J, Adham M. Palliative therapy in pancreatic cancer – palliative surgery. Transl Gastroenterol Hepatol 2019; 4: 28. doi: 10.21037/ tgh.2019.04.03.

42. Moss A, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. In: Mac Mathuna P. Cochrane Database of Syst Rev 2006; CD004200. doi: 10.1002/14651858.CD004200.pub2.

43. Ryska M. Preoperative staging in patients with pancreatic cancer. Gastroenterol a Hepatol 2015; 69 (6): 525–529. doi: 10.14735/AMGH2015525.

44. Kraus M, Kovala P, Kremer M. Využití EUS navigované choledochoduodenostomie v léčbě biliární obstrukce. Gastroent Hepatol 2014; 68 (2): 146–148.

45. Nosek V, Pintová J. EUS navigované gastrointestinální anastomózy – nové možnosti terapeutické endoskopie. Gastroent Hepatol 2020; 74 (4): 302–310. doi: 10.14735/amgh2020302.